Analysts at William Blair upped their FY2024 earnings per share (EPS) estimates for shares of Cheesecake Factory in a ...

Research analysts at William Blair decreased their FY2025 earnings per share (EPS) estimates for shares of AbbVie in a note ...

Fintel reports that on January 23, 2025, William Blair downgraded their outlook for Parsons (NYSE:PSN) from Outperform to Market Perform. Analyst Price Forecast Suggests 30.87% Upside As of December ...

Fintel reports that on January 22, 2025, William Blair downgraded their outlook for Charles River Laboratories International ...

Parsons Corp. (PSN) is sinking 9% today after investment bank William Blair cut its rating on the name to Market Perform from Outperform.

William Blair downgraded Charles River (CRL) to Market Perform from Outperform without a price target “There is simply too much working against Charles River in the near term to make the stock ...

At this past week’s ICR Conference in Orlando, cautious optimism floated beneath the current of two, inflation-strapped years ...

William Blair downgraded Charles River Laboratories to market perform citing concerns over a decline in early-stage R&D funding from large pharmas. Read more here.

Stephanie Braming, global head of investment management at William Blair, plans to retire in the fourth quarter, a news release said. She joined the Chicago-based firm in 2004 as a portfolio manager ...

William Blair has recently reduced Applied Therapeutics Inc (APLT) stock to Mkt Perform rating, as announced on December 23, 2024, according to Finviz. Earlier, on December 2, 2024, UBS had reduced ...

Vigil Neuroscience's VG-3927 Phase 1 trial shows strong safety, 50% sTREM2 reduction, and potential Alzheimer's treatment; Phase 2 begins Q3 2025.

Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...